Survival after brain metastases in Asian patients with HER2+breast cancer

被引：4
作者：
Yap, Y. S.
Devi, B. C.
Khorprasert, C.
Cornelio, G. H.
Sutandyo, N.
Yeoh, E.
Landis, S.
Kobayashi, M.
Moon, H.
Ro, J.
机构：
[1] Natl Canc Ctr, Singapore, Singapore
[2] Sarawak Gen Hosp, Sarawak, Malaysia
[3] Chulalongkorn Univ, Bangkok 10330, Thailand
[4] San Juan Dios Hosp, Pasay City, Philippines
[5] Darmais Canc Ctr Hosp, Jakarta, Indonesia
[6] GlaxoSmithKline, Singapore, Singapore
[7] GlaxoSmithKline, Stockley Pk, England
[8] GlaxoSmithKline, Res Triangle Pk, NC USA
[9] GlaxoSmithKline Pte Ltd, Seoul, South Korea
[10] Natl Canc Ctr, Ctr Breast Canc, Goyang, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
543
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Improved survival after radiotherapy for brain metastases in patients with HER2 positive breast tumors.
    Maur, M
    Frassoldati, A
    Piacentini, F
    Ramundo, D
    Sabbatini, R
    Giovannelli, S
    Ficarra, G
    Bertolini, F
    Falchi, AM
    Conte, PF
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S182 - S182
  • [32] COSTS OF RECURRENCE IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Albanell, J.
    Colomer, R.
    Martin, M.
    Martinez, D.
    Arroyo, I
    Moreno, E.
    VALUE IN HEALTH, 2020, 23 : S435 - S435
  • [33] HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients
    Wolstenholme, Virginia
    Hawkins, Maria
    Ashley, Sue
    Tait, Diana
    Ross, Gillian
    BREAST, 2008, 17 (06) : 661 - 665
  • [34] RESULTS OF ANTI-HER 2 THERAPIES AFTER BRAIN METASTASES ON THE PROGNOSIS IN BREAST CANCER PATIENTS
    Widera, Karolina
    Nowicka, Elzbieta
    Jarzab, Michal
    Gabrys, Dorota
    BREAST, 2023, 71 : S55 - S56
  • [35] HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients
    Wolstenholme, V.
    Hawkins, M. A.
    Ross, G. M.
    Tait, D. M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 217 - 217
  • [36] Impact of Tucatinib on Progression Free Survival in Patients with HER2+Metastatic Breast Cancer and Brain Metastases
    Loibl, Sibylle
    Lin, Nancy
    Murthy, Rashmi K.
    Hurvitz, Sara A.
    Borges, Virginia
    Oliveria, Mafalda
    Oakman, Catherine
    Khan, Sarah
    Lynch, Cynthia
    Westbrook, Kelly
    Doyle, Catherine
    Reinisch, Mattea
    Callenoni, Marco
    Slamon, Dennis
    Hortobagyi, Gabriel
    Winer, Eric
    Ramos, Jorge
    Feng, Wentao
    Bachelot, Thomas
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 26 - 26
  • [37] Combination therapy could improve survival of HER2-postive breast cancer patients with brain metastases
    Milburn, Joanna
    BREAST CANCER MANAGEMENT, 2013, 2 (01) : 11 - 11
  • [38] Impact of tucatinib on progression free survival in patients with HER2+metastatic breast cancer and brain metastases
    Reinisch, M.
    Bachelot, T.
    Lin, N. U.
    Murthy, R. K.
    Hurvitz, S.
    Borges, V
    Oliveira, M.
    Oakman, C.
    Khan, S.
    Lynch, C.
    Westbrook, K.
    Doyle, C.
    Colleoni, M.
    Slamon, D.
    Hortobagyi, G.
    Winer, E.
    Ramos, J.
    Feng, W.
    Loibl, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 242 - 243
  • [39] Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer
    Bartsch, Rupert
    Rottenfusser, Andrea
    Wenzel, Catharina
    Dieckmann, Karin
    Pluschnig, Ursula
    Altorjai, Gabriela
    Rudas, Margaretha
    Mader, Robert M.
    Poetter, Richard
    Zielinski, Christoph C.
    Steger, Guenther G.
    JOURNAL OF NEURO-ONCOLOGY, 2007, 85 (03) : 311 - 317
  • [40] Effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival
    Niwinska, A.
    Tacikowska, M.
    Lemanska, I.
    Pienkowski, T.
    Murawska, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345